Research ArticleCancer

The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma

See allHide authors and affiliations

Science Translational Medicine  29 Jul 2020:
Vol. 12, Issue 554, eaaz3339
DOI: 10.1126/scitranslmed.aaz3339

Fighting multiple myeloma with multitargeted T cells

Adoptive cellular therapies are being developed to treat many types of cancer, including multiple myeloma (MM). Lulla et al. performed a clinical study using T cells expanded in response to MM target antigens. The cells were used as adjuvant therapy or in high-risk patients. Therapy was well tolerated and induced clinical responses in a subset of patients. Examination of T cell clonal expansion and antigen loss in MM cells aided understanding of how the multiantigen-targeted T cells were behaving in patients. This approach, which relies on native T cells and does not require expensive or time-consuming gene editing required for some other types of cellular therapy, warrants further investigation for fighting MM.

View Full Text

Stay Connected to Science Translational Medicine